MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Suletud

SektorTervishoid

1.71 -4.47

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.71

Max

1.71

Põhinäitajad
By Trading Economics
Sissetulek	-2.8M -16M
Müük	-8.7M 5.5M
Kasumimarginaal	-282.723
Töötajad	81
EBITDA	-4.2M -15M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+122.67% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	22M 674M
Eelmine avamishind	6.18
Eelmine sulgemishind	1.71

Uudiste sentiment

By Acuity

41%

59%

120 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. apr 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Nikkei Likely to Fall After U.S.-Iran Peace Talks Break Down -- Market Talk

12. apr 2026, 23:38 UTC

Market Talk

Uudisväärsed sündmused

Oil Climbs as U.S.-Iran Peace Talks Fail, U.S. Navy Starts Blockade of Strait of Hormuz -- Market Talk

12. apr 2026, 23:38 UTC

Market Talk

Australia's Upstream Energy Companies Poised for Consensus Earnings Upgrades -- Market Talk

12. apr 2026, 23:36 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls as Dollar Strengthens After U.S.-Iran Peace Talks Collapse -- Market Talk

12. apr 2026, 23:31 UTC

Market Talk

A2 Milk's Supply Issues Likely Temporary -- Market Talk

12. apr 2026, 23:09 UTC

Market Talk

Uudisväärsed sündmused

Australian Dollar Hammered by Blockade of Iran Ports -- Market Talk

12. apr 2026, 23:06 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. apr 2026, 23:06 UTC

Market Talk

Australian Dollar Ripe for a Downward Correction -- Market Talk

12. apr 2026, 22:56 UTC

Uudisväärsed sündmused

Spot Gold Falls 1.9% to $4,658.65 per Ounce

12. apr 2026, 22:54 UTC

Uudisväärsed sündmused

Front-Month Brent Crude Oil Futures Rise 7.6% to $102.42 per Barrel

12. apr 2026, 22:53 UTC

Uudisväärsed sündmused

Front-Month WTI Crude Oil Futures Rise 8.3% to $104.56 per Barrel, ICE Data Show

12. apr 2026, 22:51 UTC

Uudisväärsed sündmused

Front-Month Crude Oil Futures Climb After U.S.-Iran Peace Talks Break Down

12. apr 2026, 22:50 UTC

Market Talk

Uudisväärsed sündmused

US Dollar Climbs Amid Broad Risk Off Mood In FX Market -- Market Talk

12. apr 2026, 22:37 UTC

Market Talk

Uudisväärsed sündmused

Australian Dollar Under Fire as Middle East Tensions Ratchet Up Again -- Market Talk

11. apr 2026, 08:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

11. apr 2026, 08:20 UTC

Market Talk

Health Care Roundup: Market Talk

11. apr 2026, 08:20 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

11. apr 2026, 00:00 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Big Yachts, Big Bucks -- Barrons.com

10. apr 2026, 21:55 UTC

Omandamised, ülevõtmised, äriostud

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10. apr 2026, 21:01 UTC

Tulu

Cango Inc.: Files Annual Report on Form 20-F With SEC

10. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10. apr 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

10. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. apr 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10. apr 2026, 20:10 UTC

Omandamised, ülevõtmised, äriostud

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10. apr 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10. apr 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10. apr 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10. apr 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10. apr 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

122.67% tõus

12 kuu keskmine prognoos

Keskmine 3.83 USD 122.67%

Kõrge 6 USD

Madal 1 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

120 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.